CELZ Latest Report

Financial Performance

Creative Medical (stock code: CELZ) recorded a total operating revenue of RMB30 million in 2024, the same as in 2023. Despite the unchanged total operating revenue, other financial indicators showed challenges in the company's profitability and cash flow. This indicates that the company failed to achieve growth in sales revenue, possibly affected by market competition or low internal management efficiency.

Key Financial Data

1. The total operating revenue in 2024 was RMB30 million, the same as in 2023, indicating weak revenue growth.

2. Marketing, sales, and general management expenses were high, at RMB14.1569 million in 2024 and RMB14.2423 million in 2023, possibly squeezing the company's profit margin.

3. Research and development expenses increased to RMB4.7184 million, from RMB3.49408 million in 2023, affecting cash flow and profitability in the short term but contributing to long-term product innovation.

4. The impact of medical insurance policies was evident, with the proportion of medical insurance settlement revenue decreasing from 52% in 2022 to 44% in 2024, negatively affecting operating revenue.

Industry Comparison

1. Overall industry analysis: The entire industry's operating revenue faces challenges in weak growth due to market saturation, increased competition, etc. The overall revenue growth rate slows down, making it difficult to cover the rigid growth of store expenses.

2. Peer evaluation analysis: Compared with other companies in the industry, Creative Medical's operating revenue remained unchanged, possibly indicating its poor competitive position in the market or its products failing to meet market demand, leading to a lack of revenue growth.

Summary

Creative Medical's operating revenue failed to grow in 2024, mainly due to increased market competition, the impact of medical insurance policies, and high management expenses. Although the company has invested in research and development, it may be difficult to translate it into significant revenue growth in the short term.

Opportunities

1. Continued growth in research and development investment may lay a foundation for the company's future product development and revenue growth.

2. Through the conversion of self-developed projects, it is expected to bring more revenue elasticity to the company, further enhancing market competitiveness.

3. If effective measures can be taken to respond to changes in medical insurance policies and market competition, new profit growth points may be found.

Risks

1. Continued market competition and the impact of medical insurance policies may continue to suppress the company's revenue growth.

2. High management expenses may continue to squeeze the company's profit margin, affecting long-term profitability.

3. Short-term losses in research and development investment may affect the company's cash flow situation for a period of time.